Tracks outcomes of alectinib after surgery for early lung cancer
Observes adults with ALK-positive early lung cancer treated with alectinib after surgery.
Plain-language title generated from the registry record
Registry title: Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
Key facts
- Where
- Beijing, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Huzhou, Jiangmen, Jinan, Kaifeng, Lanzhou, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shengyang, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Ürümqi, Wuhan, Wuxi, Xi'an, Yinchuan, Zhanjiang, Zhengzhou, and Zunyi, ChinaSee the 44 sites
Where in China
- Peking University First HospitalBeijing, ChinaTaking people
- Xuanwu Hospital, Capital Medical UniversityBeijing, ChinaNo longer taking part
- Hunan Cancer HospitalChangsha, ChinaTaking people
- Changzhou First People's HospitalChangzhou, ChinaTaking people
- Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples HospitalChengdu, ChinaTaking people
- The First Affiliated Hospital, Chongqing Medical UniversityChongqing, ChinaTaking people
- The Second Affiliated Hospital of Dalian Medical UniversityDalian, ChinaTaking people
- Fujian Cancer HospitalFuzhou, ChinaTaking people
- Affiliated Cancer Hospital and Institute of Guangzhou Medical UniversityGuangzhou, ChinaTaking people
- The Third Affiliated Hospital of Sun Yat-Sen UniversityGuangzhou, ChinaTaking people
- The Second Affiliated Hospital, Zhejiang UniversityHangzhou, ChinaTaking people
- Zhejiang Cancer HospitalHangzhou, ChinaTaking people
- Harbin Medical University Cancer HospitalHarbin, ChinaTaking people
- Anhui Provincial HospitalHefei, ChinaTaking people
- Huzhou Central HospitalHuzhou, ChinaTaking people
- Jiangmen Central HospitalJiangmen, ChinaTaking people
- Shandong Provincial HospitalJinan, ChinaTaking people
- Huai He Hospital of Henan UniversityKaifeng, ChinaTaking people
- Lanzhou University Second HospitalLanzhou, ChinaTaking people
- The First Affiliated Hospital of NanChang UniversityNanchang, ChinaTaking people
- Jiangsu Cancer HospitalNanjing, ChinaTaking people
- Jiangsu Province HospitalNanjing, ChinaTaking people
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical SchoolNanjing, ChinaTaking people
- Affiliated Hospital of Nantong UniversityNantong, ChinaTaking people
- Ningbo No.2 HospitalNingbo, ChinaTaking people
- Shanghai Chest HospitalShanghai, ChinaTaking people
- Shanghai Pulmonary HospitalShanghai, ChinaTaking people
- Zhongshan Hospital,Fudan UniversityShanghai, ChinaTaking people
- Liaoning Provincial Cancer HospitalShengyang, ChinaTaking people
- Cancer Hospital Chinese Academy Of Medical Sciences, Shenzhen CenterShenzhen, ChinaTaking people
- Hebei Medical University Fourth HospitalShijiazhuang, ChinaTaking people
- Shanxi Provincial Cancer HospitalTaiyuan, ChinaTaking people
- Taizhou Hospital of Zhejiang ProvinceTaizhou, ChinaTaking people
- Chest disease hospital of Tianjin CityTianjin, ChinaTaking people
- The First Affiliated Hospital of Xinjiang Medical UniversityÜrümqi, ChinaTaking people
- Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & TechnologyWuhan, ChinaTaking people
- Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaTaking people
- Wuxi People's HospitalWuxi, ChinaTaking people
- The Second Affiliated Hospital of Xi'an Jiao Tong UniversityXi'an, ChinaTaking people
- Xi'an International Medical Center HospitalXi'an, ChinaTaking people
- General Hospital of Ningxia Medical UniversityYinchuan, ChinaTaking people
- Affiliated Hospital of Guangdong Medical UniversityZhanjiang, ChinaTaking people
- Henan Provincial Chest HospitalZhengzhou, ChinaTaking people
- Affiliated Hospital of Zunyi Medical UniversityZunyi, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hoffmann-La Roche
- Trial code
- NCT06862869
- Record updated
- 5 November 2026
- Original description
This study is a multicenter, prospective, cohort study designed to evaluate the clinical outcomes and characteristics of resected stage II-IIIB anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) adult patients treated with Alectinib as adjuvant therapy in China.Read full original descriptionShow less
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy in China: A Multicenter, Prospective Cohort Study
This study is a multicenter, prospective, cohort study designed to evaluate the clinical outcomes and characteristics of resected stage II-IIIB anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) adult patients treated with Alectinib as adjuvant therapy in China.
Inclusion: Histologically-confirmed stage II-IIIA or selected IIIB (T3N2) NSCLC as per the American Joint Committee on Cancer and International Union Against Cancer (UICC/AJCC), 8th edition; ALK positive; Postoperative NSCLC patients who have undergone complete resection; Had taken Alectinib monotherapy without prior systemic therapy (including other ALK-TKIs or chemotherapy) as adjuvant† therapy for resected stage II-IIIB ALKpositive NSCLC and the time from the first dose to enrollment was no more than 28 days.
Exclusion: Patients participating in interventional study of adjuvant treatment; Pregnant, lactating, or breastfeeding women.